NCT05920356

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2023-11-16Est. Completion: 2027-06-30

Enrollment target: 750 participants

Locations

Sansum Clinic, Santa Barbara, California, United States
Medical Oncology Hematology Consultants Helen F Graham Cancer Center, Newark, Delaware, United States
Boca Raton Clinical Research Coral Springs, Coral Springs, Florida, United States
Florida Clinical Trials Group Plantation, Plantation, Florida, United States
Florida Clinical Trials Group Tamarac, Tamarac, Florida, United States
University of Illinois Chicago, Chicago, Illinois, United States
Illinois Cancer Specialists, Niles, Illinois, United States
Norton Cancer Institute - Brownsboro, Louisville, Kentucky, United States
Reliant Medical Group Inc, Worcester, Massachusetts, United States
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Messino Cancer Centers Asheville, Asheville, North Carolina, United States
Duke University Medical Center, Durham, North Carolina, United States
FirstHealth Cancer Center, Pinehurst, North Carolina, United States
Dayton Physician's Network, Dayton, Ohio, United States

Other microbiome trials you might be interested in

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesPhase 1Recruiting

Advanced Solid TumorLocally Advanced Solid TumorMetastatic Solid TumorPlatinum-resistant Ovarian CancerPost Anti-PD-1 Melanoma2L+ Cervical CancerNeoadjuvant MelanomaNeoadjuvant Non-Small Cell Lung CancerPost Anti-PD-(L)1 Non-Small Cell Lung CancerPost Anti-PD-(L)1 Small Cell Lung CancerThird Line or Later (3L+) HER2+ Breast CancerSecond or Third Line (2L/3L) Cervical CancerThird-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)

TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumor…

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.